Sujeong Kim

This inventor holds 16 USPTO granted patents and 8 published patent applications, plus 6 CIPO patents and 10 EPO patents, primarily in Biomedical Engineering. Top assignees: Kolon Life Science, Inc., Samsung Electronics Co., Ltd., Viromed Co., Ltd.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sujeong Kim. Retrieved from https://idiyas.com/inventor/sujeong-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 8)

% Patents Active = 87.5

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Hwaseong-si, KR (2023)
Seoul, KR (2009 - 2024)

Company Filing History:

6 out of 10

Kolon Life Science, Inc.

patents

6 out of 138,671

Samsung Electronics Co., Ltd.

Kolon Tissuegene, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Pain Treatment

Memory Devices

Recombinant Viruses

Fusion Proteins

Biological Molecules

Integrated Circuits

DNA Formulations

Poxvirus Promoters

Device-to-Device Interfaces

Electronic Systems

Data Training

Inflammatory Diseases

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12636346 - COMPOSITION FOR TREATING PAIN (2026-05-26),

2. 12501621 - Semiconductor device and electronic system therewith (2025-12-16),

3. 12189560 - Apparatus and method for training device-to-device physical interface (2025-01-07),

4. 12119049 - Memory controller performing data training, system-on-chip including the memory controller, and operating method of the memory controller (2024-10-15),

5. 12062606 - Memory device (2024-08-13),

6. 11862624 - Integrated circuit device with protective antenna diodes integrated therein (2024-01-02),

7. 11830541 - Memory controller performing data training, system-on-chip including the memory controller, and operating method of the memory controller (2023-11-28),

8. 11452770 - Recombinant vaccinia virus and use thereof (2022-09-27),

9. 11433145 - Composition for treating pain (2022-09-06),

10. 11191787 - Composition for treating inflammatory disease induced by hyperimmune response (2021-12-07),

11. 11001860 - Poxvirus-derived promoter, and vector comprising same (2021-05-11),

12. 10898590 - Method for delivery of biological molecule to nervous tissue (2021-01-26),

13. 8389492 - Lyophilized DNA formulations for enhanced expression of plasmid DNA (2013-03-05),

14. 8106158 - Compositions and methods for fusion protein separation (2012-01-31),

15. 8105575 - Expression vectors with improved safety (2012-01-31),

Title: Sujeong Kim: Innovator in Cancer Treatment

Introduction

Sujeong Kim is a notable inventor from South Korea, recognized for his contributions to the field of cancer treatment through innovative technologies. His work primarily focuses on recombinant vaccinia viruses, which have shown promising results in targeting cancer cells while minimizing harm to normal cells.

Latest Patents

Sujeong Kim has developed several significant patents, including:

1. **Recombinant Vaccinia Virus And Pharmaceutical Composition Comprising Same** - This invention relates to a recombinant vaccinia virus that includes a gene encoding sPD-1 or hyaluronidase. The virus is designed to suppress the expression of certain genes, resulting in an effective anti-tumor effect, making it a valuable tool in cancer therapy.

2. **Recombinant Vaccinia Virus And Use Thereof** - This patent describes a recombinant vaccinia virus that selectively targets and kills cancer cells. It boasts excellent reproducibility in cancer cells and lower toxicity to normal cells, highlighting its potential as a safe and effective treatment option for cancer patients.

Career Highlights

Throughout his career, Sujeong Kim has worked with prominent companies in the biotechnology sector. He has been associated with Kolon Life Science, Inc. and Viromed Co., Ltd., where he has contributed to the advancement of medical technologies aimed at improving patient outcomes.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Sujeong Kim's innovative work in developing recombinant vaccinia viruses represents a significant advancement in cancer treatment. His contributions have the potential to improve the safety and efficacy of cancer therapies, making a lasting impact in the field of medicine.

Profile summary based on public USPTO records.